NASDAQ:ASMB Assembly Biosciences (ASMB) Stock Price, News & Analysis $23.67 0.00 (0.00%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$23.72 +0.04 (+0.19%) As of 09/25/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Assembly Biosciences Stock (NASDAQ:ASMB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Assembly Biosciences alerts:Sign Up Key Stats Today's Range$23.43▼$24.2550-Day Range$23.66▼$36.7252-Week Range$21.80▼$39.71Volume143,522 shsAverage Volume381,638 shsMarket Capitalization$481.92 millionP/E Ratio23.21Dividend YieldN/APrice Target$47.50Consensus RatingModerate Buy Company Overview Assembly Biosciences, Inc. is a clinical-stage biotechnology company developing oral therapies for serious viral infections. Its research programs have focused primarily on chronic hepatitis B virus (HBV) infection and herpesvirus diseases, with the goal of addressing areas where existing treatments may not provide a functional cure or durable disease control. The company’s pipeline includes investigational HBV capsid assembly modulators, including ABI-4334, designed to interfere with key stages of the HBV lifecycle. Assembly is also developing antiviral candidates for herpes simplex virus (HSV), including ABI-5366, a long-acting helicase-primase inhibitor intended to prevent viral replication. These programs remain investigational and are subject to clinical and regulatory evaluation. Assembly Biosciences has historically advanced its programs through a combination of internal research and strategic collaboration. The company entered into a collaboration with Gilead Sciences covering certain HBV research and development activities. Assembly is led by William M. Collier, who serves as president and chief executive officer.AI Generated. May Contain Errors. Read More Assembly Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreASMB MarketRank™: Assembly Biosciences scored higher than 73% of companies evaluated by MarketBeat, and ranked 188th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingAssembly Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAssembly Biosciences has a consensus price target of $47.50, representing about 100.7% upside from its current price of $23.67.Amount of Analyst CoverageAssembly Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Assembly Biosciences' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-97.81% Earnings GrowthEarnings for Assembly Biosciences are expected to decrease by -97.81% in the coming year, from $2.28 to $0.05 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Assembly Biosciences is 23.21, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.92.Price to Earnings Ratio vs. SectorThe P/E ratio of Assembly Biosciences is 23.21, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 276.19.Price to Book Value per Share RatioAssembly Biosciences has a P/B Ratio of 1.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Assembly Biosciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.67% of the float of Assembly Biosciences has been sold short.Short Interest Ratio / Days to CoverAssembly Biosciences has a short interest ratio ("days to cover") of 6.26.Change versus previous monthShort interest in Assembly Biosciences has recently decreased by 1.16%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAssembly Biosciences does not currently pay a dividend.Dividend GrowthAssembly Biosciences does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment1.48 News SentimentAssembly Biosciences has a news sentiment score of 1.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Assembly Biosciences this week, compared to 3 articles on an average week.Search Interest5 people have searched for ASMB on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Assembly Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Assembly Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders3.50% of the stock of Assembly Biosciences is held by insiders.Percentage Held by Institutions19.92% of the stock of Assembly Biosciences is held by institutions.Read more about Assembly Biosciences' insider trading history. Receive ASMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Assembly Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ASMB Stock News HeadlinesAssembly Biosciences (ASMB) Receives a Buy from Mizuho SecuritiesSeptember 12, 2026 | theglobeandmail.comAssembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment ConferenceSeptember 10, 2026 | markets.businessinsider.comIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every dollar while paying savers just 0.04 percent interest. A new law, the GENIUS Act signed last summer, has cleared the way for a different kind of money to emerge this fall, one that could offer savings rates up to 6 percent. See what Ian King, Chief Strategist at Strategic Fortunes, has uncovered about this shift before it goes live.September 28 at 1:00 AM | Banyan Hill Publishing (Ad)Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment ConferenceSeptember 10, 2026 | globenewswire.comAssembly Biosciences Exercises Option to Share US Costs, Profits for Herpes Program With GileadSeptember 8, 2026 | finance.yahoo.comAssembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor ProgramSeptember 8, 2026 | globenewswire.comUBS initiates coverage of Assembly Biosciences (ASMB) with buy recommendationSeptember 2, 2026 | msn.comAssembly Biosciences: Gilead Advancements For GS-1179 And ABI-6250 Is A Bullish SignalAugust 16, 2026 | seekingalpha.comSee More Headlines ASMB Stock Analysis - Frequently Asked Questions How have ASMB shares performed this year? Assembly Biosciences' stock was trading at $34.01 at the beginning of the year. Since then, ASMB shares have decreased by 30.4% and is now trading at $23.67. How were Assembly Biosciences' earnings last quarter? Assembly Biosciences, Inc. (NASDAQ:ASMB) issued its quarterly earnings results on Thursday, August, 13th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.52. The biopharmaceutical company earned $13.37 million during the quarter, compared to analyst estimates of $8.60 million. Assembly Biosciences had a negative trailing twelve-month return on equity of 0.02% and a negative net margin of 0.06%. When did Assembly Biosciences' stock split? Assembly Biosciences shares reverse split on Monday, February 12th 2024.The 1-12 reverse split was announced on Monday, February 12th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. When did Assembly Biosciences IPO? Assembly Biosciences (ASMB) raised $19 million in an initial public offering on Thursday, December 16th 2010. The company issued 2,900,000 shares at $6.00-$7.00 per share. Who are Assembly Biosciences' major shareholders? Top institutional shareholders of Assembly Biosciences include Seven Fleet Capital Management LP (2.13%), Squarepoint Ops LLC (0.17%), Bank of New York Mellon Corp (0.15%) and Engineers Gate Manager LP (0.09%). Insiders that own company stock include Alexander Schornstein, John G Mchutchison, Jason A Okazaki, Jeanette M Bjorkquist, Nicole S White and Michael Houghton. View institutional ownership trends. How do I buy shares of Assembly Biosciences? Shares of ASMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Assembly Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Assembly Biosciences investors own include Waste Connections (WCN), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), AUO (AUOTY), American Water Works (AWK), The RMR Group (RMR) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings8/13/2026Today9/28/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 13 days, ASMB's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ASMB CIK1426800 Webwww.assemblybio.com Phone(833) 509-4583Fax646-706-5101Employees73Year Founded2005Price Target and Rating Average Price Target for Assembly Biosciences$47.50 High Price Target$52.00 Low Price Target$43.00 Potential Upside/Downside+100.7%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)$1.02 Trailing P/E Ratio23.21 Forward P/E Ratio10.38 P/E GrowthN/ANet Income-$6.12 million Net Margins-0.06% Pretax Margin-0.06% Return on Equity-0.02% Return on Assets-0.02% Debt Debt-to-Equity RatioN/A Current Ratio13.99 Quick Ratio13.99 Sales & Book Value Annual Sales$72.30 million Price / Sales6.67 Cash FlowN/A Price / Cash FlowN/A Book Value$13.04 per share Price / Book1.82Miscellaneous Outstanding Shares20,360,000Free Float19,648,000Market Cap$481.92 million OptionableOptionable Beta1.13 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:ASMB) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersArizona Gold Explorer Nears First-Ever Resource EstimateA little-known Arizona gold explorer just hit 66.2 metres grading 6.57 g/t gold, including 20.7 metres at 18.2...Wall Street Logic | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredShould You Convert a Traditional IRA to a Roth After 60?Considering a Roth conversion after 60? The upside includes no income limits on conversions, potential tax-fre...SmartAsset | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assembly Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Assembly Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ASMB Stock Alerts